Nina Horowitz
Chief Executive Officer ImmuneBridge
Nina Horowitz is a bioengineer with research experience in disciplines ranging from evolutionary biology to cancer immunology. She worked in laboratories at Williams College, Mount Sinai, Boston University, and Stanford University before joining the ImmuneBridge team. Her doctoral research centered around the uses of engineered natural killer cells for solid tumor immunotherapy. At ImmuneBridge, she is leading the development of a novel internal pipeline as well as a variety of co-developed therapeutics for cancer, autoimmune, neurodegeneration, and other diseases.
Seminars
- Applying AI-driven analysis to develop predictive models of donor performance
- Leveraging machine learning models to guide CAR-NK engineering and manufacturing decisions
- Integrating machine learning into preclinical and clinical workflows to continuously improve product efficacy
A dynamic opening discussion featuring CEOs and founders at the forefront of innate immunity and NK-cell innovation. This high-level session sets the tone for the meeting as industry leaders examine the current landscape, emerging scientific and commercial inflection points, and the path to translating innate immune breakthroughs into meaningful therapeutic impact. Through candid insights and forward-looking perspectives, the panel will outline the opportunities, challenges, and decisive moves that will shape the field over the next 3–5 years.
- The milestones that brought innate therapies to today’s inflection point
- What’s driving the next wave of NK and innate innovation
- Scientific and clinical hurdles that must be overcome
- Strategic priorities in a shifting funding and regulatory climate
- Commercial pathways and competitive positioning for the next era
